Endurant Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Endurant Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-58,240	Closed	-$558K	–	76
2018 Q4	$558K	Sell	58,240 -12,528	-18%	-$138K	0.29%	44
2018 Q3	$856K	Buy	70,768 +16,264	+30%	+$227K	0.38%	50
2018 Q2	$851K	Sell	54,504 -72,496	-57%	-$1.1M	0.37%	49
2018 Q1	$1.91M	Sell	127,000 -79,400	-38%	-$1.21M	0.71%	37
2017 Q4	$2.97M	Buy	+206,400	New	+$2.84M	0.91%	40
2017 Q3	–	Sell	-118,800	Closed	-$1.57M	–	92
2017 Q2	$1.2M	Sell	118,800 -104,500	-47%	-$841K	0.34%	62
2017 Q1	$1.59M	Sell	223,300 -2,000	-0.9%	-$12.6K	0.51%	53
2016 Q4	$1.12M	Buy	225,300 +182,400	+425%	+$1.26M	0.46%	48
2016 Q3	$317K	Buy	+42,900	New	+$290K	0.12%	88

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Endurant Capital Management's FOLD Position: Q1 2019 in Review

Endurant Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 58,240 shares — an estimated $558K sold.

Endurant Capital Management first reported a position in FOLD in Q3 2016 and held it in 9 quarters. The position peaked at $2.97M in Q4 2017. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

Endurant Capital Management reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
Endurant Capital Management sold 58,240 Amicus Therapeutics shares in Q1 2019, an estimated $558K.
Endurant Capital Management first reported a position in Amicus Therapeutics in Q3 2016 and held it in 9 quarters.
Endurant Capital Management's Amicus Therapeutics position peaked at $2.97M in Q4 2017.
205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.